Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
05 sept. 2024 06h30 HE
|
Merakris Therapeutics
Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.
Negative Pressure Wound Therapy (NPWT) Devices Market to Surpass US$ 3,789.9 Million by 2030, Says Coherent Market Insights (CMI)
20 févr. 2023 09h15 HE
|
CMI
Burlingame, Feb. 20, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global negative pressure wound therapy (NPWT) devices market is estimated to be valued at US$ 2,288.1 million...
Global Negative Pressure Wound Therapy (NPWT) Devices Market to Surpass US$ 4,318.7 Million by 2030, Says Coherent Market Insights (CMI)
16 août 2022 09h40 HE
|
CMI
Seattle, Aug. 16, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global negative pressure wound therapy (NPWT) devices market is estimated to be valued at US$ 2,560.2 million in...
Merakris Therapeutics, Inc. Announces FDA Clearance for Dermacyte® Liquid Clinical Trial
25 mai 2021 09h00 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Merakris Therapeutics, Inc. (Merakris) announced that it has received U.S. Food and Drug Administration (FDA) clearance for a Phase II...